GB Sciences Company Profile (OTCMKTS:GBLX)

About GB Sciences (OTCMKTS:GBLX)

GB Sciences logoGB Sciences, Inc., formerly Growblox Sciences, Inc., is engaged in developing and utilizing technologies in plant biology, cultivation and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies and treatments for a range of ailments. It intends to conduct its business operations, through its subsidiaries in approximately three operating units, which include Solutions, Sciences and Product divisions. The Solutions division involves the development and use of its suite of controlled-climate indoor agricultural technology growing and cultivation Suites, including TissueBLOX, GrowBLOX, CureBLOX and ExtractionLAB. The Science division is engaged in preclinical testing of its biopharmaceutical cannabinoid product prototypes to begin future human clinical trials.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:GBLX
  • CUSIP: N/A
  • Web:
  • Market Cap: $34.45 million
  • Outstanding Shares: 127,746,000
Average Prices:
  • 50 Day Moving Avg: $0.25
  • 200 Day Moving Avg: $0.28
  • 52 Week Range: $0.21 - $0.65
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $54,099.00
  • Price / Sales: 636.85
  • Book Value: $0.06 per share
  • Price / Book: 4.73
  • EBIDTA: ($10,010,000.00)
  • Net Margins: -5,761.07%
  • Return on Equity: -158.06%
  • Return on Assets: -100.57%
  • Average Volume: 296,694 shs.

Frequently Asked Questions for GB Sciences (OTCMKTS:GBLX)

What is GB Sciences' stock symbol?

GB Sciences trades on the OTCMKTS under the ticker symbol "GBLX."

How were GB Sciences' earnings last quarter?

GB Sciences Inc (OTCMKTS:GBLX) released its quarterly earnings data on Monday, November, 14th. The company reported ($0.04) earnings per share for the quarter. GB Sciences had a negative net margin of 5,761.07% and a negative return on equity of 158.06%. View GB Sciences' Earnings History.

Who are some of GB Sciences' key competitors?

Who are GB Sciences' key executives?

GB Sciences' management team includes the folowing people:

  • John Poss, Chairman of the Board, President, Chief Executive Officer, Chief Operating Officer
  • Leslie Bocskor, Vice Chairman of the Board
  • Ksenia Griswold, Chief Financial Officer, Vice President
  • Andrea Small-Howard Ph.D., Chief Science Officer, Director
  • Shane Terry, Independent Director

How do I buy GB Sciences stock?

Shares of GB Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GB Sciences' stock price today?

One share of GB Sciences stock can currently be purchased for approximately $0.27.

MarketBeat Community Rating for GB Sciences (OTCMKTS GBLX)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  18 (Vote Outperform)
Underperform Votes:  10 (Vote Underperform)
Total Votes:  28
MarketBeat's community ratings are surveys of what our community members think about GB Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for GB Sciences (OTCMKTS:GBLX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for GB Sciences (OTCMKTS:GBLX)
No equities research coverage for this company has been tracked by


Earnings History for GB Sciences (OTCMKTS:GBLX)
Earnings by Quarter for GB Sciences (OTCMKTS:GBLX)
Earnings History by Quarter for GB Sciences (OTCMKTS GBLX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2016Q2 2017($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for GB Sciences (OTCMKTS:GBLX)

No earnings estimates for this company have been tracked by


Dividend History for GB Sciences (OTCMKTS:GBLX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for GB Sciences (OTCMKTS:GBLX)
Insider Trades by Quarter for GB Sciences (OTCMKTS:GBLX)
Insider Trades by Quarter for GB Sciences (OTCMKTS:GBLX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/4/2017Craig EllinsInsiderSell100,000$0.26$26,000.00View SEC Filing  
10/6/2016Lazarus Management Co LlcMajor ShareholderSell785,000$0.31$243,350.00View SEC Filing  
10/8/2014Lazarus Management Co LlcMajor ShareholderBuy77,700$0.69$53,613.00View SEC Filing  
10/2/2014Lazarus Management Co LlcMajor ShareholderBuy39,605$0.85$33,664.25View SEC Filing  
9/29/2014Lazarus Management Co LlcMajor ShareholderBuy64,000$0.90$57,600.00View SEC Filing  
9/17/2014Lazarus Management Co LlcMajor ShareholderBuy47,640$0.76$36,206.40View SEC Filing  
8/27/2014Israel Opportunities F LazarusMajor ShareholderBuy46,625$1.05$48,956.25View SEC Filing  
8/1/2014Israel Opportunities F LazarusMajor ShareholderBuy39,800$1.24$49,352.00View SEC Filing  
7/30/2014Israel Opportunities F LazarusMajor ShareholderBuy87,077$1.24$107,975.48View SEC Filing  
7/2/2014Lazarus Investment Partners LlMajor ShareholderBuy269,632$1.19$320,862.08View SEC Filing  
6/2/2014Lazarus Management Co LlcMajor ShareholderBuy1,000,000$0.50$500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for GB Sciences (OTCMKTS:GBLX)
Latest Headlines for GB Sciences (OTCMKTS:GBLX)
DateHeadline logoInnovative Partnership Forged Between LSU AgCenter And GB Sciences To Advance The Understanding Of The Cannabis Plant - September 18 at 6:30 PM logoGroundbreaking Collaboration Between A Major University And A Medical Cannabis Company - September 18 at 6:30 PM logoGB Sciences Inc (GBLX) Insider Sells $26,000.00 in Stock - August 7 at 8:02 PM logoGB Sciences Joins With Los Coyotes Band Of Cahuilla And Cupeno Indians As It Enters The Gigantic California Cannabis Market - August 2 at 7:49 PM logoGB Sciences initiates cannabis-based therapy clinical trials consulting services agreement with Worldwide Clinical Trials - July 17 at 9:30 AM logoGB Sciences Initiates Cannabis-based Therapy Clinical Trials Consulting Services Agreement with Worldwide Clinical Trials, Inc. - July 17 at 9:30 AM logoGB Sciences Inc. Adds Provisional Nevada Recreational Cannabis License for Branded Recreational Products - July 10 at 6:53 AM logoCannabis Industry Weekly Recap 7/7/2017 - July 8 at 10:59 AM logoGB Sciences Sells First Cannabis Harvest and Officially Enters Revenue Mode - July 5 at 7:32 AM logoGB Sciences Wins Louisiana State University (LSU) Bid to Act as LSU Agricultural Center's Exclusive Operator of Medical Cannabis Production Facility - June 26 at 9:34 AM logoGB Sciences Builds Broad Cannabis Patent Portfolio -- CFN Media - June 16 at 6:05 PM logoGB Sciences Announced As LSU Bid Winner - June 16 at 6:05 PM logoGB Sciences Files Patent Application for Chronic Pain and Heart Therapies - May 23 at 11:51 AM logoGB Sciences Celebrates Their First Las Vegas Harvest - May 16 at 11:37 AM logoGB Sciences Revered Founder, Craig Ellins, Retires - May 9 at 11:37 AM logoCannabis, CBD, Vape Products See Uptick in Sales in Thriving Legal Marijuana Markets - May 4 at 12:14 PM logoGB Sciences Surpasses Key Corporate Milestones, Plus Exclusive CEO Interview -- CFN Media - May 2 at 7:08 PM logoGB Sciences Partners with Kush Cups to Produce Cannabis-Infused Keurig-Compatible K-Cups, Brewed Coffee and Infused Tea - April 10 at 11:26 AM logoGB Sciences Submits Offer to Louisiana State University (LSU) for Providing the Cultivation, Extraction, Processing and Production of Medical Cannabis Pursuant to the Alison Neustrom Act - April 3 at 5:35 PM logoGB Sciences Moves Closer to Clinical Trials -- CFN Media - March 28 at 11:41 AM logoMarijuana Stocks: How CEOs Can Navigate Market Volatility (And Survive Spicer And Sessions) - March 10 at 11:30 PM logoWhy Cannabinoids Work Best Together -- CFN Media - March 7 at 11:27 AM logoGROWBLOX SCIENCES, INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement - February 16 at 5:19 PM logoGB Sciences Embraces Cannabinoid Complexities, Plus New Interview -- CFN Media - February 9 at 6:00 PM logoGB Sciences Files Patent Application for the Treatment of Chronic Arthritis, Crohn's Disease, Inflammatory Bowel Disease, and Asthma; Proprietary Cannabinoid-Containing Complex Mixtures for the Treatment of Inflammatory Disorders - February 6 at 11:13 AM logoGB Sciences Resets: Exclusive Executive Interview with CFN Media - January 23 at 10:27 AM logoLeveraging the Cultivation and Medicinal Value of Cannabis - GB Sciences - January 18 at 5:47 PM logoGB Sciences (GBLX): A Grow Business with a Moonshot in Biopharma -- CFN Media - January 6 at 5:54 PM logoGB Sciences Announces Opening of Las Vegas, Nevada, Indoor Cannabis Grow, Moving GB Sciences into a Revenue Generating Stage - January 4 at 4:35 PM logoGROWBLOX SCIENCES, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year - December 20 at 9:47 PM logoGB Sciences, Inc. Engages CFN Media to Cultivate Long Term Investor Audience - December 15 at 5:56 PM logoGB Sciences Licenses Patent To Develop New Cannabis-Based Therapies For The Treatment Of Heart Disease - December 13 at 11:06 AM logoCannabis Stocks Stay Ahead In Exploding Legal Marijuana Market - November 29 at 5:07 PM logoCannabis Legalization at the Forefront this Week - November 9 at 11:07 AM logoPot is on the Ballot in Election 2016, but Investors Should Proceed with Caution - October 27 at 9:50 AM logoGROWBLOX SCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders - October 15 at 9:58 AM logoGrowblox Sciences Announces Patent Application for Treatments of Parkinson's Disease, Alzheimer's Disease, Huntington's Disease and Dementia - October 12 at 10:10 AM logoLetter from CEO of Growblox Sciences Regarding Annual Meeting of Shareholders - October 11 at 5:24 PM logoGrowblox Sciences, Inc. Acquires Two Additional Medical Cannabis Cultivation And Production Establishment Licenses In The State Of Nevada - October 4 at 9:58 AM logoAwareness Continues to Grow for Medical Uses of Cannabis - September 29 at 10:10 AM logoGROWBLOX SCIENCES, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities - September 9 at 4:59 PM logoGROWBLOX SCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Princi - August 11 at 5:24 PM logoGrowblox Sciences, Inc. with Pacific Leaf Partners LLC, Announces Ownership of Flagship Teco Medical Cannabis Growing Facility - July 26 at 8:30 AM logoLetter To Growblox Sciences, Inc. Shareholders From Its CEO - July 25 at 8:30 AM logoGrowblox Sciences Forms Growblox Life Sciences, LLC, A Research Organization Focused on Medical Cannabis Scientific Discoveries - July 19 at 9:30 AM logoGROWBLOX SCIENCES, INC. Files SEC form 10-K, Annual Report - July 14 at 5:31 PM logoGrowblox Sciences, Inc. Announces The Opening Of Its First Medical Marijuana Dispensary: "Showgrow" In Las Vegas, Nevada - June 28 at 9:30 AM logoGROWBLOX SCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement - June 7 at 5:17 PM logoGrowBLOX Sciences, Inc. Announces Exclusive Rights To Kyle Kushman's Cannabis Brands, Strains And Genetics In The State Of Nevada - June 7 at 9:48 AM



GB Sciences (GBLX) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by Staff